Assessment of the Rheumatoid Factor Titers in Extra-Articular Manifestation of Rheumatoid Arthritis

Introduction: Rheumatoid arthritis (RA) is a chronicmultisystem disease of unknown cause. The characteristicfeature of RA is persistent inflammatory synovitis usuallyinvolving the peripheral joints in a symmetric fashion.Hence;the present study was undertaken for assessing rheumatoidfactor titers in extra-articular manifestation of rheumatoidarthritis.Material and methods: A total number of 50 patientswho met the inclusion criteria were included in this study.Rheumatoid arthritis diagnosed as per 2010 revised criteriafor the classification of RA were enrolled. The RA patientsthus selected were screened for various common clinicalfeatures, articular and extra-articular manifestations usinga structured Proforma designed for this study. At the end ofthe study the titers of RF factor in articular and extra articularmanifestations in 50 rheumatoid arthritis patients screenedwere calculated and expressed as percentage. All the resultswere recorded in Microsoft excel sheet and were analysed bySPSS software.Results: The clinical examination in the study revealedpallor in 34(68%) patients. Rheumatoid factor titres of 1:16were observed in 4(13%) of patients, 1:32 in 7(24%), 1:64 in8(28%) and 1;128 in 10(35%) of patients. Hemoglobin <8g/dl in 10 patients i.e.;(20%), 8-10g/dl in 14 patients i.e;40%,10-12g/dl in 10 patients i.e.; 28%. (Normal Hb 12-14g/dlin females, 14-16g/dl in males). Peripheral smear showed24 patients i.e 70% of them had normocytic normochromicanemia. Extra-articular manifestations were seen in about72%, Anemia in 34(68%), Lymphadenopathy in 8(16%),Purpuric –rash in 4(8%), Rheumatoid nodules in 4(8%) andSplenomegaly in 2(4%).Conclusion: Extra-articular manifestations contributesignificantly to the morbidity and mortality in rheumatoidarthritis. Careful screening of all patients for extra-articularmanifestations may help reduce the same, with the propermanagement of such patients

Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative Study / 대한핵의학회잡지

PURPOSE: The aim of the study was to compare response evaluation criteria in solid tumours 1.1 (RECIST 1.1), positron emission tomography response criteria in solid tumours (PERCIST), European organisation for research and treatment of cancer (EORTC), andMDAnderson (MDA) criteria for response assessment by Gallium 68-prostate-specific membrane antigen positron emission tomography-computed tomography (Ga68-PSMA PET-CT) in metastatic adenocarcinoma prostate cancer (mPCa) patients with biochemical progression.METHODS: Eighty-eight mPCa patients with pre and post treatment Ga68-PSMA PET-CTwere included. A ≥ 25% increase and ≥ 2 ng/ml above the nadir if prostate specific antigen (PSA) drop or ≥ 2 ng/ml above the baseline if PSA does not drop was considered as biochemical progression. RECIST 1.1 and MDA criteria for morphology and PERCIST and EORTC criteria for molecular response were investigated. Percentages of progressive disease (PD), partial response (PR), and stable disease (SD) were calculated. Chi-square test was used for statistical significance.RESULTS: Proportion of PD, SD, and PR by RECIST 1.1 and MDA criteria were 44 (50.57%), 39 (44.83%), 4 (4.6%), and 33 (39.76%), 48 (57.83%), 2 (2.41%) respectively. Proportion of PD, SD, and PR by PERCIST and EORTC criteria were 71 (80.68%), 11 (12.50%), 6 (6.82%), and 74 (84.09%), 8 (9.09%), 6 (6.82%) respectively. Chi-square test showed statistically significant (P < 0.05) higher proportion of progression detected by both molecular criteria as compare to both morphological criteria.CONCLUSION: We concluded that for Ga68-PSMA PET-CT response evaluation, molecular criteria performed better than morphological criteria in mPCa patient with PSA progression.

Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative Study / 대한핵의학회잡지

PURPOSE@#The aim of the study was to compare response evaluation criteria in solid tumours 1.1 (RECIST 1.1), positron emission tomography response criteria in solid tumours (PERCIST), European organisation for research and treatment of cancer (EORTC), andMDAnderson (MDA) criteria for response assessment by Gallium 68-prostate-specific membrane antigen positron emission tomography-computed tomography (Ga68-PSMA PET-CT) in metastatic adenocarcinoma prostate cancer (mPCa) patients with biochemical progression.@*METHODS@#Eighty-eight mPCa patients with pre and post treatment Ga68-PSMA PET-CTwere included. A ≥ 25% increase and ≥ 2 ng/ml above the nadir if prostate specific antigen (PSA) drop or ≥ 2 ng/ml above the baseline if PSA does not drop was considered as biochemical progression. RECIST 1.1 and MDA criteria for morphology and PERCIST and EORTC criteria for molecular response were investigated. Percentages of progressive disease (PD), partial response (PR), and stable disease (SD) were calculated. Chi-square test was used for statistical significance.@*RESULTS@#Proportion of PD, SD, and PR by RECIST 1.1 and MDA criteria were 44 (50.57%), 39 (44.83%), 4 (4.6%), and 33 (39.76%), 48 (57.83%), 2 (2.41%) respectively. Proportion of PD, SD, and PR by PERCIST and EORTC criteria were 71 (80.68%), 11 (12.50%), 6 (6.82%), and 74 (84.09%), 8 (9.09%), 6 (6.82%) respectively. Chi-square test showed statistically significant (P < 0.05) higher proportion of progression detected by both molecular criteria as compare to both morphological criteria.@*CONCLUSION@#We concluded that for Ga68-PSMA PET-CT response evaluation, molecular criteria performed better than morphological criteria in mPCa patient with PSA progression.